Dr. Gregory Marshall Heestand, MD

Dr. Heestand practices at Stanford Hospital at 300 Pasteur Drive in Stanford, California, part of Stanford University.

Dr. Heestand's NPI, 1770568867, was assigned on December 12, 2005. Dr. Heestand graduated from Keck School of Medicine of USC in 2004. Dr. Heestand holds California license A92666.

Dr. Heestand's primary practice is Stanford Hospital at 300 Pasteur Drive, at 300 Pasteur Drive, Stanford, CA 94305 in Santa Clara County. The practice phone is (650) 723-4000.

Dr. Heestand's primary practice is Stanford Hospital at 300 Pasteur Drive in Stanford, California, part of Stanford University. The medical group on file is Stanford Health Care. Dmand AI also links Dr. Heestand to 1 more hospital, 1 home health agency and 1 medical group, each named with a free account. Dr. Heestand's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Heestand practices, 3 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Heestand's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Heestand is board certified in medical oncology by the American Board of Internal Medicine. Dr. Heestand is licensed in California.

Dmand AI lists anemia, breast cancer, colorectal cancer, lung cancer, multiple myeloma and prostate cancer among the conditions Dr. Heestand treats.

CMS data shows 636 Medicare services from Dr. Heestand across 8 procedure codes in 2024, for 196 Medicare patients. Medicare paid $79,674 for them.

CMS counts 196 Medicare patients who saw Dr. Heestand in 2024. The largest group is 65 to 74, with 89 patients. 75% of them have high blood pressure, and 66% have high cholesterol. 33% are also on Medicaid. Their average risk score is 2.67, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Heestand's median patient age at 67, with 42% women.

In 2024, Dr. Heestand wrote 91 Medicare Part D claims for 30 patients. 84% of them were for generic drugs. CMS names the drug for 27 of them, across 2 drugs with 11 or more claims each, at $273 in total drug cost. In 2022, CMS named 15 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 89 out of 100 for Dr. Heestand for performance year 2024, reported as part of a group. Dr. Heestand accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Heestand as offering telehealth.

Upper gastrointestinal (GI) endoscopy for acid reflux: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 21 papers to Dr. Heestand, published from 2012 to 2025. 2017 was the busiest year, with 3. The most frequent topics are Biomarkers, Tumor, Antineoplastic Combined Chemotherapy Protocols and Pancreatic Neoplasms. Dr. Heestand has published most often in Phys Rev Lett. Dr. Heestand's most frequent co-authors are Daniel Tandel Chang, MD, Shalini Dixit and Paul Timothy Fanta, MD.

Dmand AI links Dr. Heestand to 2 clinical trials. Conditions studied include Adenocarcinoma Of Esophagus, Gallbladder Neoplasms and Gallbladder Diseases.

CMS Open Payments shows 56 general payments to Dr. Heestand from 9 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 33% of the total. Exelixis Inc. paid the most, $13,212.

Dr. Heestand graduated from Keck School of Medicine of USC in 2004.

Dr. Heestand is in network with 8 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Blue Cross Blue Shield of Massachusetts. Medicare plans come from the most carriers, 6. Check the plan with the practice before a visit.